Symbollon Pharmaceuticals’s Iogen(TM) Available for Sale on Amazon.com

MEDFIELD, MA--(Marketwire - March 30, 2010) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) (www.symbollon.com) is pleased to announce that Iogen™ is now available for sale on Amazon.com®. Iogen™ is a patented dietary supplement for improving women’s breast health. Symbollon markets and sells Iogen™ through its retail website, www.buyiogen.com. Iogen™ is the first dietary supplement formulated to promote breast health for women.

“We are actively looking to broaden the retail outlets for Iogen™,” stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. “Listing Iogen on Amazon.com® is just the start of our internet marketing efforts. We are also sponsored search partners with Google and Yahoo. Through these sponsored searches, Iogen™ is able to receive first page listing on searches based on all relevant search terms related to breast health. This is a great advertising tool for us to get Iogen™ in front of millions of women in need. We continue to pursuing additional retail distribution channels for our product. We are committed to making Iogen™ available in as many outlets as possible so every woman who has interest in improving her breast health has easy access to it.”

About Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA)
Symbollon is a specialty biotechnology company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women’s healthcare and antimicrobial uses. For more information about Symbollon, please visit the company’s website at http://www.symbollon.com or for more product information or to purchase Iogen, visit www.buyiogen.com.

Forward Looking Statement This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to successfully commercialize Iogen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) we will be able to complete the acquisition of New Zealand Pure under the terms of the letter of intent, (v) Symbollon will be able to commercialize other products and (vi) such other factors as may be disclosed from time-to-time in the Company’s reports as filed with the Securities and Exchange Commission.